Financial Data and Key Metrics Changes - The company reported a net loss of $33.5 million or $0.58 per share for the first quarter of 2025, compared to a net loss of $31.4 million or $0.54 per share in the fourth quarter of the previous year [5][18] - As of March 31, 2025, the company had $52.4 million in cash and investments on hand [18] - The company entered into an exchange agreement to convert approximately $71 million of 2026 convertible notes into new 9.5% convertible senior notes due in 2029, significantly improving financial flexibility [5][19] Business Line Data and Key Metrics Changes - Research and development expenses in the first quarter were primarily focused on narsoplimab and zaltanibart [20] - OMIDRIA royalties for the first quarter totaled $6.7 million based on net sales of $22.3 million, a decrease from $10.1 million in royalties on net sales of $33.6 million in the previous quarter [22][23] Market Data and Key Metrics Changes - The market opportunity for narsoplimab is estimated at nearly $1 billion annually, with expectations for it to become a cornerstone asset for transplant experts [11] - The global market for paroxysmal nocturnal hemoglobinuria (PNH) is projected to grow to over $10 billion by 2032, with significant unmet needs in the complement inhibitor market [12] Company Strategy and Development Direction - The company is focused on the anticipated approval and launch of narsoplimab for the treatment of TATMA, with a target FDA action date of September 25 [8] - The company is also developing zaltanibart for PNH, with ongoing clinical trials and a temporary pause on the phase three program due to capital considerations [12][14] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of managing costs and maintaining liquidity while advancing key initiatives [7] - The company is actively pursuing partnerships for non-dilutive funding to support operations and the launch of narsoplimab [6] Other Important Information - The FDA has accepted the resubmitted BLA for narsoplimab, and the company is preparing for a successful launch [8] - The company is suspending its expanded access program for narsoplimab to focus resources on the successful launch [9][10] Q&A Session Summary Question: Can you provide details on launch plans and patient access? - Management expressed confidence in the launch preparations, highlighting engagement with key transplant centers and payers [29][31][34] Question: Can you detail the patient demographics and associated costs? - Management explained that TATMA is a complication of stem cell transplants that can arise unpredictably, leading to significant healthcare costs [41][42] - The economic value of narsoplimab was discussed, emphasizing its potential to reduce costs associated with untreated patients [44][45]

Financial Data and Key Metrics Changes - The company reported a net loss of $33.5 million or $0.58 per share for the first quarter of 2025, compared to a net loss of $31.4 million or $0.54 per share in the fourth quarter of the previous year [5][19] - As of March 31, 2025, the company had $52.5 million in cash and investments on hand [5][19] - The company has reduced its total outstanding debt by $10 million and lowered its near-term repayment obligations from approximately $118 million to $17 million [6][20] Business Line Data and Key Metrics Changes - Research and development expenses in the first quarter were heavily focused on narsoplimab and zaltanibart [21] - OMIDRIA royalties for the first quarter totaled $6.7 million based on net sales of $22.3 million, a decrease from $10.1 million in royalties on net sales of $33.6 million in the previous quarter [23][24] Market Data and Key Metrics Changes - The market opportunity for narsoplimab is estimated at nearly $1 billion annually, with expectations for it to become a cornerstone asset for transplant experts [12] - The global market for paroxysmal nocturnal hemoglobinuria (PNH) is projected to grow about 11% annually to over $10 billion by 2032 [13] Company Strategy and Development Direction - The company is focused on the successful launch of narsoplimab for the treatment of TATMA, following the anticipated FDA approval [8][9] - The company is also developing zaltanibart, targeting PNH, while managing costs and pausing certain programs to prioritize resources [14][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming launch of narsoplimab, highlighting the preparation and engagement with key transplant centers and payers [35][36] - The company is committed to managing cash and liquidity effectively to support operations and capitalize on growth opportunities [7][49] Other Important Information - The FDA has accepted the resubmitted BLA for narsoplimab, with a target action date of September 25 [9] - The company is also working on a marketing authorization application for narsoplimab in Europe, targeting submission later this quarter [10] Q&A Session Summary Question: Can you provide details on launch plans and patient access? - Management indicated that the commercial team is well-prepared for the launch, focusing on key transplant centers and engaging with payers for product information exchanges [30][31][35] Question: Can you elaborate on the patients affected by TATMA and associated costs? - Management explained that TATMA is a complication of stem cell transplants that can arise unpredictably, leading to significant healthcare costs due to the severity of the condition [38][44] - The economic value of narsoplimab is highlighted by its potential to reduce costs associated with untreated patients, emphasizing outpatient treatment benefits [46][47]

Core Viewpoint - Southern Cross Gold Consolidated Ltd has announced an upsized private placement of approximately C$143 million/AUD$162 million to fund its strategic Sunday Creek Gold-Antimony Project, reflecting strong demand from institutional and existing investors [1][3][8]. Proposed Placement - The company aims to raise approximately C$143 million through a private placement of 31.8 million common shares at C$4.50 per share and/or Chess Depositary Interests (CDIs) at A$5.10 per CDI [3][4]. - The placement will not require shareholder approval and will be conducted under the company's placement capacity according to ASX listing rules [4]. Pricing and Discounts - The issue price for the CDIs represents an approximate 8.9% discount to the last closing price on April 28, 2025, and an 8.3% discount to the 5-day volume weighted average price prior to a trading halt [5]. - The issue price for the Common Shares represents a 4.1% discount to the last closing price on April 29, 2025, and a 5.0% discount to the 5-day volume weighted average price prior to the trading halt [6]. Timeline and Conditions - The issuance of the Securities is expected to occur in two tranches: Tranche 1 on May 6, 2025, for CDIs and Tranche 2 on May 14, 2025, for the remaining Common Shares [7]. - All Securities will be subject to a four-month hold period from the closing date [7]. Use of Funds - The net proceeds from the placement will be allocated to key milestones for the Sunday Creek Gold-Antimony Project, including: - C$53 million for drilling to establish an Inferred Resource by Q1 2027 - C$27 million for decline development to enhance access to mineralization - C$4 million for a Preliminary Economic Assessment - C$59 million for exploration target expansion and working capital over three years [8][18]. Strategic Importance - The Sunday Creek project is positioned as a significant gold and antimony discovery, with antimony contributing 20% of the in-situ value, which has gained importance due to geopolitical factors affecting supply [16][17]. - The project is expected to be developed primarily based on gold economics, reducing risks associated with antimony while maintaining strategic supply potential [17].